Neuromodulation to Facilitate the Effect of Ketamine

Depression Clinical Trial

— TMS/ketamine  

Official title:

Treatment of Thalamocortical Dysrhythmia Using External Neuromodulation to Facilitate the Therapeutic Effect of Ketamine.

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01816958
• Other study ID #: 12_1293
• Status: Completed
• Phase: N/A
• First received: March 11, 2013
• Last updated: March 20, 2013
• Start date: January 2011
• Est. completion date: November 2012

Study information

• Verified date: March 2013
• Source: The Neuroscience Center, LLC
• Contact: n/a
• Is FDA regulated: No
• Health authority: United States: Institutional Review Board
• Study type: Observational

Clinical Trial Summary

application of external neuromodulation along with ketamine infusion.

Description:

apply TMS concurrent with ketamine infusion in order to increase the likliehood & strength of therapeutic benefit

Recruitment information / eligibility

• Status: Completed
• Enrollment: 35
• Est. completion date: November 2012
• Est. primary completion date: November 2012
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• chronically ill,

• treatment-resistant

Exclusion Criteria:

• active psychosis

Study Design

Observational Model: Case Control, Time Perspective: Retrospective

Related Conditions & MeSH terms

• Chronic Pain
• Depression
• Substance Abuse

Intervention

Other:
• co-administration of TMS and infused ketamine
co-administration of TMS and infused ketamine

Locations

Country	Name	City	State
United States	The Neuroscience Center	Deerfield	Illinois

Sponsors (1)

Lead Sponsor	Collaborator
The Neuroscience Center, LLC

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Global Assessment of Function in DSM-4R	treat in order to cause remission of disability	up to 3 years	No